Ado-Trastuzumab Emtansine

Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.

Also Known As:

Kadcyla; huN901-DM1; Ado Trastuzumab Emtansine; Trastuzumab DM1; Trastuzumab DM1 Conjugate; huN901 DM1; huN901DM1; Trastuzumab Emtansine; Trastuzumab-DM1; Trastuzumab-DM1 Conjugate

Organic Chemicals: 133
- Lactones: 1549
  - Macrolides: 4391
    - Maytansine: 145
      - Ado-Trastuzumab Emtansine: 626
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Macrocyclic Lactams: 28
    - Maytansine: 145
      - Ado-Trastuzumab Emtansine: 626
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Trastuzumab: 9058
        Ado-Trastuzumab Emtansine: 626
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Trastuzumab: 9058
        Ado-Trastuzumab Emtansine: 626
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Trastuzumab: 9058
        Ado-Trastuzumab Emtansine: 626

E Sharon Selected Research

E Sharon Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure